Home > Publications database > Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging. > print

001     304239
005     20250831022529.0
024 7 _ |a 10.1182/bloodadvances.2025016510
|2 doi
024 7 _ |a pmid:40590883
|2 pmid
024 7 _ |a 2473-9529
|2 ISSN
024 7 _ |a 2473-9537
|2 ISSN
024 7 _ |a altmetric:179507776
|2 altmetric
037 _ _ |a DKFZ-2025-01798
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Schinke, Carolina
|0 0000-0002-2699-1741
|b 0
245 _ _ |a Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging.
260 _ _ |a Washington, DC
|c 2025
|b American Society of Hematology
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1756387539_18473
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #LA:A360#
520 _ _ |a Multiple myeloma (MM) is a heterogeneous disease exemplified by focal lesions (FLs), densely populated nodules whose number and persistence during treatment predict poor outcome. However, the prognostic role of FL location and the relationship between FLs at different time points remain underexplored, although they may provide critical clues to disease evolution and resistance mechanisms. We analyzed positron emission tomography (PET) and diffusion-weighted magnetic resonance imaging (DWI) scans from 243 patients with MM enrolled in total therapies at baseline, after autologous stem cell transplant (ASCT), and every 6 to 12 months thereafter until relapse or last follow-up. Baseline FLs in the humerus or femur were associated with poor prognosis. Although rare, residual PET-positive FLs after ASCT identified patients with worse outcomes. One-third of patients had residual FLs on DWI after ASCT, which also correlated with poor prognosis. Even FLs that resolved after the second ASCT in patients who underwent tandem ASCTs retained adverse prognostic significance, highlighting the limitations of late imaging in high-risk patients. Patients who achieved both minimal residual disease (MRD) and imaging negativity after ASCT had the best outcomes. Conversely, MRD-negative patients with FLs had as poor outcomes as double-positive patients. Residual FLs persisting to relapse were predominantly observed in early relapse cases, and resolved FLs frequently recurred at the same or nearby sites, suggesting limited imaging sensitivity for detection of focal resistant cells. Taken together, this study identifies long bone FLs as a risk factor, and underscores the value of serial imaging and the urgent need for alternative treatment strategies for patients with persistent FLs.
536 _ _ |a 311 - Zellbiologie und Tumorbiologie (POF4-311)
|0 G:(DE-HGF)POF4-311
|c POF4-311
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Multiple Myeloma: therapy
|2 MeSH
650 _ 2 |a Multiple Myeloma: diagnostic imaging
|2 MeSH
650 _ 2 |a Multiple Myeloma: mortality
|2 MeSH
650 _ 2 |a Multiple Myeloma: pathology
|2 MeSH
650 _ 2 |a Multiple Myeloma: diagnosis
|2 MeSH
650 _ 2 |a Prognosis
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Positron-Emission Tomography: methods
|2 MeSH
650 _ 2 |a Diffusion Magnetic Resonance Imaging: methods
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Neoplasm, Residual
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
700 1 _ |a Rasche, Leo
|0 0000-0002-9536-9649
|b 1
700 1 _ |a Ashby, Cody
|b 2
700 1 _ |a van Hemert, Rudy
|b 3
700 1 _ |a Thanendrarajan, Sharmilan
|b 4
700 1 _ |a Al Hadidi, Samer
|b 5
700 1 _ |a Zangari, Maurizio
|b 6
700 1 _ |a Bailey, Clyde
|b 7
700 1 _ |a Alapat, Daisy V
|b 8
700 1 _ |a Shaughnessy, John D
|b 9
700 1 _ |a Zhan, Fenghuang
|0 0000-0001-5417-2973
|b 10
700 1 _ |a Barlogie, Bart
|b 11
700 1 _ |a van Rhee, Frits
|b 12
700 1 _ |a Weinhold, Niels
|0 P:(DE-He78)66b39a79f3f922997656d7b902d324fb
|b 13
|e Last author
|u dkfz
773 _ _ |a 10.1182/bloodadvances.2025016510
|g Vol. 9, no. 17, p. 4368 - 4377
|0 PERI:(DE-600)2876449-3
|n 17
|p 4368 - 4377
|t Blood advances
|v 9
|y 2025
|x 2473-9529
909 C O |o oai:inrepo02.dkfz.de:304239
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)66b39a79f3f922997656d7b902d324fb
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-311
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Zellbiologie und Tumorbiologie
|x 0
914 1 _ |y 2025
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BLOOD ADV : 2022
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-07-05T12:07:28Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-07-05T12:07:28Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-07-05T12:07:28Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-16
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-16
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b BLOOD ADV : 2022
|d 2024-12-16
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-16
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-16
920 2 _ |0 I:(DE-He78)A360-20160331
|k A360
|l KKE Mol. Hämatologie/Onkologie
|x 0
920 1 _ |0 I:(DE-He78)A360-20160331
|k A360
|l KKE Mol. Hämatologie/Onkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A360-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21